Core Viewpoint - West Pharmaceutical Services (WST) has experienced a bearish trend recently, losing 6.1% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which supports a bullish outlook for the stock [2][5]. - A hammer pattern forms when there is a small difference between opening and closing prices, with a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for WST, which is a bullish indicator, as it typically leads to price appreciation [7]. - The consensus EPS estimate for the current year has increased by 0.2% over the last 30 days, indicating strong agreement among analysts regarding the company's improved earnings potential [8]. - WST holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperforms the market [9][10].

Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] - In fiscal year 2024, West generated $2.89 billion in net sales and is traded on the New York Stock Exchange (NYSE: WST) [5] Upcoming Financial Results - West Pharmaceutical Services will release its fourth-quarter and full-year 2025 financial results before the market opens on February 12, 2026 [1] - A conference call to discuss the results and business expectations will take place at 8:00 a.m. Eastern Time on the same day [1] Investor Engagement - A live webcast of the conference call will be available, and participants must register in advance to ask questions [2] - A slide presentation will be accessible in the Investors section of the company's website on the day of the call, with a replay available for approximately 90 days after the event [3]

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and West Pharmaceutical Services (WST) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a prove ...

Core Viewpoint - West Pharmaceutical Services (WST) stock is currently in a support zone, which has historically led to significant rebounds, making it a stock to watch [2][3] Technical Analysis - WST stock has attracted buying interest at the current support level seven times over the last decade, yielding an average peak return of 34.7% [3] - The stock is technically oversold with a Relative Strength Index (RSI) of 27.1 and is near its 52-week low [4] - Analyst consensus is "Buy," with average price targets suggesting a potential upside of over 40% [4] Financial Performance - WST has consistently exceeded earnings per share (EPS) estimates, with solid growth anticipated in 2025 and 2026 [4] - The company reported a revenue growth of 4.9% for the last twelve months (LTM) and a 1.3% average growth over the last three years [10] - WST has a free cash flow margin of nearly 12.6% and an operating margin of 20.9% for LTM [10] - The stock trades at a price-to-earnings (PE) multiple of 34.8 [10] Market Position and Strategy - The recent launch of the Synchrony S1 product targets the growing market for pre-fillable syringes, which is expected to grow at a compound annual growth rate (CAGR) of 11.6% [4] - A strategic divestiture of SmartDose is aimed at optimizing the company's portfolio [4] - Despite a forecasted short-term slowdown in the broader pharmaceutical manufacturing sector, WST's high-value segments are benefiting from strong demand trends [4]

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?AeroVironment, Inc. (NASDAQ:AVAV) decreased 19.45% this week after the US government issued a stop work order to AeroVironment on SCAR program.DraftKings Inc. (NASDAQ:DKNG) fell 14.4% this week. Sr. betting analyst Bill Speros posted on X that a judge allowed Massachusetts to block Kalshi from offering sports-related contracts in the state. He quoted the ruling saying the state can seek an injunction unless Kal ...

Key Takeaways West Pharmaceutical marked the global availability of the Synchrony S1 PFS system at Pharmapack 2026.WST's launch aligns with rising combination products and the shift from hospitals to home-based care.WST's system-level data and single DMF aim to cut development time, risk and global regulatory complexity.West Pharmaceutical Services (WST) recently announced the global commercial availability of the West Synchrony S1 prefillable syringe (PFS) system at Pharmapack 2026 in Paris, France. The ne ...

The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocking since COVID-19.In 2026, the industry is likely to see continued adoption of digital services and AI-enabled assessment tools that enhance patient experience and reduce administrative burdens for physicians. These services support faster response times t ...

West Pharmaceutical Services (WST) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed an ...

Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products For more information about Pharmapack, click here. Forward-Looking Statements Certain forward-looking statements are included in this press release. They use words such as "standard," "streamline," "accelerate," "secures," "reliable," "meets," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this re ...

Group 1: Upslope Capital Management Overview - Upslope Capital Management released its fourth-quarter 2025 investor letter, highlighting strong performance with a net return of +2.0% in Q4 compared to +1.6% for the S&P Midcap 400 ETF and HFRX Equity Hedge Index [1] - For the year 2025, the Fund achieved a return of +14.8%, outperforming the indexes which returned +7.2% and +10.1% respectively [1] - The firm noted that the market is increasingly dynamic, with investment decisions driven by aggressive, thematic, and short-term strategies [1] Group 2: West Pharmaceutical Services, Inc. (NYSE:WST) Analysis - West Pharmaceutical Services, Inc. designs and manufactures containment and delivery systems for injectable drugs, with a one-month return of -5.49% and a 52-week loss of 22.76% [2] - As of January 16, 2026, West Pharmaceutical's stock closed at $259.79, with a market capitalization of $18.69 billion [2] - Upslope Capital Management exited its position in West Pharmaceutical due to better perceived risk/reward in other healthcare investments within its portfolio [3] Group 3: Market Sentiment and Hedge Fund Interest - KeyBanc noted that West Pharmaceutical is not among the 30 most popular stocks among hedge funds, with 49 hedge fund portfolios holding the stock at the end of Q3 2025, up from 46 in the previous quarter [4] - In Q3 2025, West Pharmaceutical reported revenues of $805 million, reflecting a 5% organic growth [4] - Despite the potential of West Pharmaceutical as an investment, certain AI stocks are viewed as having greater upside potential and less downside risk [4]